Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025

Protara Therapeutics, Inc.

2023-Q2 EPS reported -$1.80

Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022
Cash, equivalents $80.4M; expected to fund operations into 2025
R&D expenses $7.2M, up from $3.1M YoY on TARA-002 clinical costs
Preliminary TARA-002 NMIBC expansion results expected 1H24; ADVANCED-2 and LM trial start 4Q23

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protara Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $11.3 million, or $1.00 per share, EPS $1.00 per share.

Period: second quarter ended June 30, 2023
Net income: net loss of $11.3 million, or $1.00 per share
EPS: $1.00 per share
Result: reported results

Exact text from the filing

For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-062780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.